Specialized Hospital For Active Treatment Of Pulmonary Diseases Troyan EOOD
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At Specialized Hospital For Active Treatment Of Pulmonary Diseases Troyan EOOD, clinical research in respiratory medicine focuses on common and high-impact lung conditions, especially chronic obstructive pulmonary disease and acute viral infections affecting the airways. The studies are designed to explore new treatment options and better ways to manage symptoms, complications, and disease worsening.
- Studies in COPD are assessing whether new add-on therapies can reduce exacerbations and improve long-term control.
- Research also includes respiratory syncytial virus infection, with attention on easing symptoms and preventing progression.
- Trials are evaluating treatment effectiveness in people with ongoing respiratory problems and a history of flare-ups.
These projects reflect the site’s strong focus on practical advances in pulmonary care, with the goal of improving outcomes for patients who are at risk of serious respiratory illness.
Virus Diseases
The Department of Pneumology in Troyan is also involved in trials targeting viral diseases, particularly COVID-19 in people at high risk of developing severe illness. This line of research aims to find therapies that may help prevent worsening disease and support recovery in nonhospitalized patients.
- One area of study is COVID-19 treatment for patients who are vulnerable to severe outcomes.
- Researchers are comparing new antiviral approaches with placebo to understand their clinical benefit.
- The work is centered on improving early intervention for viral infections before hospital care is needed.
By combining infectious disease and pulmonary research, the site contributes to better management strategies for viral illnesses that can affect breathing and overall health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specialized Hospital For Active Treatment Of Pulmonary Diseases Troyan EOOD
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) | AstraZeneca AB | Phase III | Not Recruiting | Apr 2023 | May 2026 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tozorakimab | 2 | Unknown | 2022-01-20 | 2023-04-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.